Filtered By:
Source: Circulation
Condition: Diabetes Type 2

This page shows you your search results in order of date. This is page number 3.

Order by Relevance | Date

Total 46 results found since Jan 2013.

Cardiovascular Outcomes and Risks After Initiation of a Sodium Glucose Co-Transporter 2 Inhibitor: Results From the EASEL Population-Based Cohort Study.
Conclusions : In this high-risk cohort, initiation of SGLT2i was associated with lower ACM, HHF, and MACE and higher BKA risk. Findings underscore the potential benefit and risks to be aware of when initiating SGLT2i. It remains unclear whether the BKA risk extends across the class of medication as the study was not powered to make comparisons among individual treatments. PMID: 29133607 [PubMed - as supplied by publisher]
Source: Circulation - November 13, 2017 Category: Cardiology Authors: Udell JA, Yuan Z, Rush T, Sicignano NM, Galitz M, Rosenthal N Tags: Circulation Source Type: research

Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study).
CONCLUSIONS : Patients with type 2 diabetes mellitus and prior cardiovascular events had higher rates of cardiovascular outcomes compared with the primary prevention patients. Canagliflozin reduced cardiovascular and renal outcomes with no statistical evidence of heterogeneity of the treatment effect across the primary and secondary prevention groups. Additional studies will provide further insights into the effects of canagliflozin in these patient populations. CLINICAL TRIAL REGISTRATION : URL: https://www.clinicaltrials.gov. Unique identifiers: NCT01032629 and NCT01989754. PMID: 29133604 [PubMed - as supplied by publisher]
Source: Circulation - November 13, 2017 Category: Cardiology Authors: Mahaffey KW, Neal B, Perkovic V, de Zeeuw D, Fulcher G, Erondu N, Shaw W, Fabbrini E, Sun T, Li Q, Desai M, Matthews DR, CANVAS Program Collaborative Group Tags: Circulation Source Type: research

Secondary Prevention of Cardiovascular Disease in Patients with Type 2 Diabetes: International Insights from the TECOS Trial.
Conclusions -In an international trial population, significant opportunities exist to improve the quality of cardiovascular secondary prevention care among patients with diabetes and CVD, which in turn could lead to reduced risk of downstream cardiovascular events. Clinical Trial Registration -URL: http://www.clinicaltrials.gov. Unique identifier: NCT00790205. PMID: 28626088 [PubMed - as supplied by publisher]
Source: Circulation - June 16, 2017 Category: Cardiology Authors: Pagidipati NJ, Navar AM, Pieper KS, Green JB, Bethel MA, Armstrong PW, Josse RG, McGuire DK, Lokhnygina Y, Cornel JH, Halvorsen S, Strandberg TE, Delibasi T, Holman RR, Peterson ED, TECOS Study Group Tags: Circulation Source Type: research

Causal Associations of Adiposity and Body Fat Distribution with Coronary Heart Disease, Stroke Subtypes and Type 2 Diabetes: A Mendelian Randomization Analysis.
Conclusions -Both general and central adiposity have causal effects on CHD and T2D. Central adiposity may have a stronger effect on stroke risk. Future estimates of the burden of adiposity on health should include measures of central and general adiposity. PMID: 28500271 [PubMed - as supplied by publisher]
Source: Circulation - May 12, 2017 Category: Cardiology Authors: Dale C, Fatemifar G, Palmer T, White J, Prieto-Merino D, Zabaneh D, Engmann JEL, Shah T, Wong A, Warren HR, McLachlan S, Trompet S, Moldovan M, Morris RW, Sofat R, Kumari M, Hyppönen E, Jefferis BJ, Gaunt TR, Ben-Shlomo Y, Zhou A, Gentry-Maharaj A, Ryan Tags: Circulation Source Type: research

Cardiac Outcomes After Ischemic Stroke or TIA: Effects of Pioglitazone in Patients with Insulin Resistance Without Diabetes.
Conclusions -Among patients with insulin resistance without diabetes, pioglitazone reduced the risk for acute coronary syndromes after a recent cerebrovascular event. Pioglitazone appeared to have its most prominent effect in preventing spontaneous type 1 MI's. Clinical Trial Registration - https://clinicaltrials.gov Unique Identifier: NCT00091949 US Food & Drug Administration IND: 64,622; EudraCT#2008-005546-23. PMID: 28246237 [PubMed - as supplied by publisher]
Source: Circulation - February 27, 2017 Category: Cardiology Authors: Young LH, Viscoli CM, Curtis JP, Inzucchi SE, Schwartz GG, Lovejoy AM, Furie KL, Gorman MJ, Conwit RA, Abbott JD, Jacoby DL, Kolansky DM, Pfau SE, Ling FS, Kernan WN, IRIS Investigators Tags: Circulation Source Type: research

Serial Measurement of High Sensitivity Troponin I and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus in the EXAMINE Trial.
Conclusions -Serial assessment of hsTnI revealed a substantial proportion of patients with T2DM without clinically recognized events had dynamic or persistently elevated values and were at high risk of recurrent events. hsTnI may have a role in personalizing preventive strategies in patients with diabetes based on risk. Clinical Trial Registration -https://clinicaltrials.gov Identifier: NCT00968708. PMID: 28246236 [PubMed - as supplied by publisher]
Source: Circulation - February 27, 2017 Category: Cardiology Authors: Cavender MA, White WB, Jarolim P, Bakris GL, Cushman WC, Kupfer S, Gao Q, Mehta CR, Zannad F, Cannon CP, Morrow DA Tags: Circulation Source Type: research

Preterm Delivery and Maternal Cardiovascular Disease in Young and Middle-Aged Adult Women.
CONCLUSIONS: Preterm delivery is independently predictive of CVD and may be useful for CVD prevention efforts. Because only a modest proportion of the preterm-CVD association was accounted for by development of conventional CVD risk factors, further research may identify additional pathways. PMID: 28153993 [PubMed - in process]
Source: Circulation - February 6, 2017 Category: Cardiology Authors: Tanz LJ, Stuart JJ, Williams PL, Rimm EB, Missmer SA, Rexrode KM, Mukamal KJ, Rich-Edwards JW Tags: Circulation Source Type: research

Incident Type 2 Myocardial Infarction in a Cohort of Patients Undergoing Coronary or Peripheral Arterial Angiography.
CONCLUSIONS: -T2MI is common and associated with poor prognosis. Studies evaluating treatment strategies for management of T2MI are needed.Clinical Trial Registration -https://clinicaltrials.gov/ct2/show/NCT00842868, Clinical Trials.Gov # NCT00842868. PMID: 27881568 [PubMed - as supplied by publisher]
Source: Circulation - November 20, 2016 Category: Cardiology Authors: Gaggin HK, Liu Y, Lyass A, van Kimmenade RR, Motiwala SR, Kelly N, Mallick A, Gandhi PU, Ibrahim NE, Simon M, Bhardwaj A, Belcher A, Harisiades JE, Massaro JM, D'Agostino RB, Januzzi JL Tags: Circulation Source Type: research

Low-Dose Aspirin for Primary Prevention of Cardiovascular Events in Patients with Type 2 Diabetes: 10-year Follow-up of a Randomized Controlled Trial.
CONCLUSIONS: -Low-dose aspirin did not affect the risk for cardiovascular events, but increased risk for gastrointestinal bleeding in patients with type 2 diabetes in a primary prevention setting. Clinical Trial Registration-URL: http://www.clinicaltrials.gov. Unique identifier: NCT00110448. PMID: 27881565 [PubMed - as supplied by publisher]
Source: Circulation - November 14, 2016 Category: Cardiology Authors: Saito Y, Okada S, Ogawa H, Soejima H, Sakuma M, Nakayama M, Doi N, Jinnouchi H, Waki M, Masuda I, Morimoto T, JPAD Trial Investigators Tags: Circulation Source Type: research

Sleep Duration and Quality: Impact on Lifestyle Behaviors and Cardiometabolic Health: A Scientific Statement From the American Heart Association.
in the Young; Council on Clinical Cardiology; and Stroke Council Abstract Sleep is increasingly recognized as an important lifestyle contributor to health. However, this has not always been the case, and an increasing number of Americans choose to curtail sleep in favor of other social, leisure, or work-related activities. This has resulted in a decline in average sleep duration over time. Sleep duration, mostly short sleep, and sleep disorders have emerged as being related to adverse cardiometabolic risk, including obesity, hypertension, type 2 diabetes mellitus, and cardiovascular disease. Here, we review the ev...
Source: Circulation - September 18, 2016 Category: Cardiology Authors: St-Onge MP, Grandner MA, Brown D, Conroy MB, Jean-Louis G, Coons M, Bhatt DL, American Heart Association Obesity, Behavior Change, Diabetes, and Nutrition Committees of the Council on Lifestyle and Cardiometabolic Health; Council on Cardiovascular Disease Tags: Circulation Source Type: research

Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes: Cardiovascular and Kidney Effects, Potential Mechanisms and Clinical Applications.
Abstract Sodium glucose co-transporter-2 (SGLT2) inhibitors, including empagliflozin, dapagliflozin and canagliflozin, are now widely approved anti-hyperglycemic therapies. Due to their unique glycosuric mechanism, SGLT2 inhibitors also reduce weight. Perhaps more importantly are osmotic diuretic and natriuretic effects contributing to plasma volume contraction, and decreases in systolic and diastolic blood pressures (BP) by 4-6/1-2 mmHg, respectively, which may underlie cardiovascular and kidney benefits. SGLT2 inhibition is also associated with an acute, dose-dependent reduction in eGFR by ~5 ml/min/1.73m(2) and...
Source: Circulation - July 27, 2016 Category: Cardiology Authors: Heerspink HJ, Perkins BA, Fitchett DH, Husain M, Cherney DZ Tags: Circulation Source Type: research

Bariatric Surgery: "Roux"-minating on Endothelial Cell and HDL Function.
Abstract Obesity, defined as a body mass index ≥ 30 kg/m2, is pandemic. Though prevalence in the United States has plateaued at ~31% of adults (78 million), worldwide obesity rates continue to rise(1). Perhaps more concerning is the high level of childhood obesity: 16.9% in US and ~13% (and rising) in developing countries(2). Why the alarm? Longitudinal studies of overweight or obese individuals have identified a 20 fold increase in risk for developing diabetes mellitus type 2 (T2D) and 1.5 fold increase risk for cardiovascular disease (CVD), including myocardial infarction, stroke and heart failure(3, 4). As ob...
Source: Circulation - February 11, 2015 Category: Cardiology Authors: Brown JD Tags: Circulation Source Type: research

Heart Failure, Saxagliptin and Diabetes Mellitus: Observations from the SAVOR - TIMI 53 Randomized Trial.
CONCLUSIONS: -In the context of balanced primary and secondary endpoints, saxagliptin treatment was associated with an increased risk for hospitalization for heart failure. This increase in risk was highest among patients with elevated levels of natriuretic peptides, prior heart failure, or chronic kidney disease. Clinical Trial Registration Information-ClinicalTrials.gov. Identifier: NCT01107886. PMID: 25189213 [PubMed - as supplied by publisher]
Source: Circulation - September 4, 2014 Category: Cardiology Authors: Scirica BM, Braunwald E, Raz I, Cavender MA, Morrow DA, Jarolim P, Udell JA, Mosenzon O, Im K, Umez-Eronini AA, Pollack PS, Hirshberg B, Frederich R, Lewis BS, McGuire DK, Davidson J, Steg PG, Bhatt DL, for the SAVOR-TIMI 53 Steering Committee and Investi Tags: Circulation Source Type: research

Chronic Inflammatory Disorders and Risk of Type 2 Diabetes Mellitus, Coronary Heart Disease, and Stroke: A Population-Based Cohort Study.
CONCLUSIONS: -The risk of cardiovascular diseases and T2DM is increased across a range of organ-specific and multi-system chronic inflammatory disorders with evidence that risk is associated with severity of inflammation. Clinical management of patients with chronic inflammatory disorders should aim to reduce cardiovascular risk. PMID: 24970784 [PubMed - as supplied by publisher]
Source: Circulation - June 26, 2014 Category: Cardiology Authors: Dregan A, Charlton J, Chowienczyk P, Gulliford MC Tags: Circulation Source Type: research

Effects of Visit-to-Visit Variability in Systolic Blood Pressure on Macrovascular and Microvascular Complications in Patient with Type 2 Diabetes: The ADVANCE Trial.
CONCLUSIONS: Visit-to-visit variability in SBP and maximum SBP were independent risk factors for macrovascular and microvascular complications in type 2 diabetes. CLINICAL TRIAL REGISTRATION INFORMATION: http://www.clinicaltrials.gov. Unique Identifier: NCT00145925. PMID: 23926207 [PubMed - as supplied by publisher]
Source: Circulation - August 7, 2013 Category: Cardiology Authors: Hata J, Arima H, Rothwell PM, Woodward M, Zoungas S, Anderson C, Patel A, Neal B, Glasziou P, Hamet P, Mancia G, Poulter N, Williams B, Macmahon S, Chalmers J, on behalf of the ADVANCE Collaborative Group Tags: Circulation Source Type: research